At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01801 INNOVENT BIO
Not Yet Opened 06-25 16:08:08
76.100
-1.850
-2.37%
High78.650Low74.750Vol13.50M
Open78.150D1 Closing77.950Amplitude5.00%
Mkt Cap132.26BTradable Cap132.26BTotal Shares1.74B
T/O1.03BT/O Rate0.78%Tradable Shares1.74B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Movement Alert｜Innovent Biologics Falls 3.01% in Regular Trading, Shareholder Meeting Resolutions Face High Opposition Amid Sector Weakness
Market Focus  ·  06-25 10:03
Movement Alert｜Innovent Biologics Falls 3.01% in Regular Trading, Shareholder Meeting Resolutions Face High Opposition Amid Sector Weakness
Innovent's Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of Ibi324 (oln324) in Dme and Wet Amd; Studies Commencing in Second Half of 2026
THOMSON REUTERS  ·  06-25 08:00
Innovent's Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of Ibi324 (oln324) in Dme and Wet Amd; Studies Commencing in Second Half of 2026
Innovent Biologics Files Directors List with Hong Kong Stock Exchange
Reuters  ·  06-25 06:17
Innovent Biologics Files Directors List with Hong Kong Stock Exchange
Ollin Raises $330 Million to Fund Late-stage Eye Disease Drug Trials
Reuters  ·  06-24 19:00
Ollin Raises $330 Million to Fund Late-stage Eye Disease Drug Trials
Movement Alert｜Innovent Biologics Rises 3.01% in Regular Trading, IBI3003 Phase III First Patient Dosing Continues to Drive Sentiment
Market Focus  ·  06-24 09:36
Movement Alert｜Innovent Biologics Rises 3.01% in Regular Trading, IBI3003 Phase III First Patient Dosing Continues to Drive Sentiment
JPMorgan Chase Increases Stake in Innovent Bio by Approximately 1.07 Million Shares at HK$75.40 Each
Stock News  ·  06-23 19:17
JPMorgan Chase Increases Stake in Innovent Bio by Approximately 1.07 Million Shares at HK$75.40 Each
Hong Kong Stocks Surge: Innovative Drug Sector Rallies on Regulatory Report and New Foreign Investment Policies
Stock News  ·  06-23 11:46
Hong Kong Stocks Surge: Innovative Drug Sector Rallies on Regulatory Report and New Foreign Investment Policies
Movement Alert｜Innovent Biologics Rises 3.32% in Regular Trading, IBI3003 Phase III First Patient Dosing Combined with Biotech Sector Rebound
Market Focus  ·  06-23 10:01
Movement Alert｜Innovent Biologics Rises 3.32% in Regular Trading, IBI3003 Phase III First Patient Dosing Combined with Biotech Sector Rebound
Movement Alert｜Innovent Biologics Falls 3.68% in Regular Trading, Biotechnology Sector Under Broad Selling Pressure
Market Focus  ·  06-22
Movement Alert｜Innovent Biologics Falls 3.68% in Regular Trading, Biotechnology Sector Under Broad Selling Pressure
Innovent doses first patient in Phase 3 China trial of IBI3003 tri-specific antibody for multiple myeloma
Reuters  ·  06-22
Innovent doses first patient in Phase 3 China trial of IBI3003 tri-specific antibody for multiple myeloma
Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of Ibi3003(Gprc5d/Bcma/Cd3 Tri-Specific Antibody) for the Treatment of Multiple Myeloma
THOMSON REUTERS  ·  06-22
Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of Ibi3003(Gprc5d/Bcma/Cd3 Tri-Specific Antibody) for the Treatment of Multiple Myeloma
Innovent Biologics (SEHK:1801) Stock Could Be 49% Below Fair Value After ADA Pipeline Update
Simply Wall St.  ·  06-22
Innovent Biologics (SEHK:1801) Stock Could Be 49% Below Fair Value After ADA Pipeline Update
Movement Alert｜Innovent Biologics Rises 3.07% in Regular Trading, Biotech Sector Rally and EULAR Conference Data Provide Dual Catalysts
Market Focus  ·  06-18
Movement Alert｜Innovent Biologics Rises 3.07% in Regular Trading, Biotech Sector Rally and EULAR Conference Data Provide Dual Catalysts
Novo Nordisk to seek approval soon to sell Wegovy pill in China
Reuters  ·  06-16
Novo Nordisk to seek approval soon to sell Wegovy pill in China
INNOVENT BIO Grants 5,000 Share Options and 105,200 Restricted Shares
Stock News  ·  06-15
INNOVENT BIO Grants 5,000 Share Options and 105,200 Restricted Shares
Innovent grants 105,200 restricted shares under 2024 share plan
Reuters  ·  06-15
Innovent grants 105,200 restricted shares under 2024 share plan
Movement Alert｜Innovent Biologics Rises 3.01% in Regular Trading, First Domestic PCSK9 Inhibitor Approval and ADA Data Catalyze Rebound
Market Focus  ·  06-15
Movement Alert｜Innovent Biologics Rises 3.01% in Regular Trading, First Domestic PCSK9 Inhibitor Approval and ADA Data Catalyze Rebound
Innovent Biologics (SEHK:1801) Stock Valuation After Key Obesity Data And Priority Review Cancer Milestone
Simply Wall St.  ·  06-14
Innovent Biologics (SEHK:1801) Stock Valuation After Key Obesity Data And Priority Review Cancer Milestone
Movement Alert｜Innovent Biologics Rises 3.22% in Regular Trading, Technical Rebound After Multi-Day Decline as Biotech Sector Recovers
Market Focus  ·  06-12
Movement Alert｜Innovent Biologics Rises 3.22% in Regular Trading, Technical Rebound After Multi-Day Decline as Biotech Sector Recovers
How Investors May Respond To Innovent Biologics (SEHK:1801) Advancing Oral And Extended-Interval GLP-1 Candidates
Simply Wall St.  ·  06-11
How Investors May Respond To Innovent Biologics (SEHK:1801) Advancing Oral And Extended-Interval GLP-1 Candidates

Introduction

Company Name.
INNOVENT BIO
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Innovent Biologics Inc is an investment holding company principally engaged in the research, development, production and sales of innovative medicines for the treatment of diseases such as cancer, cardiovascular and metabolic (CVM), autoimmune and eye diseases. The pipeline covering monoclonal antibodies, multi-specific antibodies, immuno-cytokine, antibody-drug conjugates (ADCs), cell therapy and small molecules. The Company’s main products include TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), Pemazyre (pemigatinib) and others. The Company mainly conducts its businesses within domestic and overseas markets.
Issue price:
--